Rheumatology Advance Access originally published online on March 14, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2003; 42: 778-783
© 2003 British Society for Rheumatology
Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study
Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK
Objective. To assess the evolution of disease subgroups and the frequency of progression of peripheral joint disease in a prospectively studied cohort of patients with psoriatic arthritis (PsA).
Methods. The cohort was identified as the first consecutive 100 patients attending a psoriatic arthritis clinic and who had been the subject of a previously published cross-sectional retrospective study. Nine of the 100 patients had died, three declined follow-up and one could not be traced. The remaining 87 patients (49 females, 38 males) completed the study proforma at a median follow-up interval of 65 months (range 39–90). An analysis of initial plasma viscosity compared with rates of progression of joint score was performed.
Results. Eighteen patients changed subgroup; 11 had an increase in the number of joints involved, six a decrease, and one changed from an oligoarticular pattern to predominant spondylitis. Within the polyarticular group 37/51 patients had an increase in the number of joints involved. For the whole population, there were significant increases in the number of joints involved (median 6 vs 11, P < 0.001 Wilcoxon signed rank) and Health Assessment Questionnaire scores (median 0.375 vs 0.5, P < 0.001). The median rate of joint progression was 0.42 peripheral joints per year (range 0–7.2). However, the rate of peripheral joint involvement was highest in the first year of arthritis (median 4.0 joints/yr) as measured in 13 patients who had onset within 12 months of baseline assessment. There were no significant differences in skin and nail scores although nine more patients had developed nail disease. There was a significant correlation between the initial viscosity and rate of progression of joint damage (Spearman correlation, P < 0.011).
Conclusions. Peripheral joint disease is progressive in the majority of patients with PsA and reinforces the need for effective monitoring and treatment.
KEY WORDS: Psoriasis, Psoriatic arthritis, Mortality, Outcome, Spondylarthropathy.
Correspondence to: N. J. McHugh. E-mail: N.J.McHugh{at}bath.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L.-S. Tam, Y.-Y. Leung, and E. K. Li Psoriatic arthritis in Asia Rheumatology, August 27, 2009; (2009) kep230v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. GLADMAN Psoriatic Arthritis from Wright's Era Until Today J Rheumatol Suppl, August 1, 2009; 83(0): 4 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. ROBINSON, S. KELLY, and C. PITZALIS Basic Synovial Biology and Immunopathology in Psoriatic Arthritis J Rheumatol Suppl, August 1, 2009; 83(0): 14 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. SCARPA, M. ATTENO, L. COSTA, R. PELUSO, S. IERVOLINO, F. CASO, and A. D. PUENTE Early Psoriatic Arthritis J Rheumatol Suppl, August 1, 2009; 83(0): 26 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Olivieri, S. de Portu, C. Salvarani, A. Cauli, E. Lubrano, A. Spadaro, F. Cantini, M. S. Cutro, A. Mathieu, M. Matucci-Cerinic, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy Rheumatology, November 1, 2008; 47(11): 1664 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cantini, L. Niccoli, C. Nannini, E. Cassara, P. Pasquetti, I. Olivieri, and C. Salvarani Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs Rheumatology, June 1, 2008; 47(6): 872 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Morgan, M. Lunt, D. Bunn, D. G. I. Scott, and D. P. M. Symmons Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis Rheumatology, December 1, 2007; 46(12): 1819 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Myers, L. J. Kay, S. A. Lynch, and D. J. Walker Recurrence risk for psoriasis and psoriatic arthritis within sibships Rheumatology, June 1, 2005; 44(6): 773 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kyle, D. Chandler, C. E. M. Griffiths, P. Helliwell, J. Lewis, I. McInnes, S. Oliver, D. Symmons, N. McHugh, and on behalf of the British Society for Rheumatology Guideline for anti-TNF-{alpha} therapy in psoriatic arthritis Rheumatology, March 1, 2005; 44(3): 390 - 397. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ravindran, P. Owen, A. Lagan, J. Lewis, E. Korendowych, K. Welsh, and N. McHugh Interleukin 1{alpha}, interleukin 1{beta} and interleukin 1 receptor gene polymorphisms in psoriatic arthritis Rheumatology, January 1, 2004; 43(1): 22 - 26. [Abstract] [Full Text] [PDF]
|
|